Lawsuits involving the birth control injection Depo-Provera are gaining national attention as more claims move through federal court. Plaintiffs allege that long-term use of the drug may be linked to brain tumors among other serious health risks.
The Depo-Provera lawsuits also allege that manufacturers failed to provide adequate warnings. As litigation continues to develop, 2026 could be a crucial year for these cases, with key rulings and early trial preparations underway.
Growing Number of Depo-Provera Lawsuits Nationwide
Depo-Provera claims have increased over the past two years, with thousands of claims now consolidated in federal court. As of early 2026, around 2,000 lawsuits have been filed in multidistrict litigation (MDL).
More cases have been centralized in federal court for efficiency and streamline pretrial proceedings. This is common practice to manage a large number of claims in mass tort cases involving dangerous drugs.
What Is Depo-Provera and How Is It Used?
Depo-Provera is an injectable form of birth control that contains medroxyprogesterone acetate. According to the Mayo Clinic, the shot is administered every three months and is commonly used for long-term contraception.
The drug has been prescribed for decades and is used by millions of individuals worldwide. However, recent litigation has raised concerns about whether certain risks associated with prolonged use were adequately disclosed.
The Main Allegation: Brain Tumors and Meningioma Risk
The primary injury alleged in Depo-Provera lawsuits is meningioma, a type of tumor that forms in the membranes surrounding the brain and spinal cord. Many meningiomas are non-cancerous, but they can still cause complications, including:
- Vision problems
- Cognitive or neurological impairment
- Persistent headaches
- Seizures
Meningioma birth control claims are that long-term Depo-Provera use may increase the risk of developing tumors. Plaintiffs also allege that they were not adequately warned about this possibility.
Recent updates have added to these concerns. According to the U.S. Food & Drug Administration, updated Depo-Provera labeling in 2025 includes warnings about reported cases of meningioma following prolonged use.
Scientific Research and Ongoing Debate
Like many pharmaceutical cases, Depo-Provera litigation involves competing interpretations of scientific evidence. Some research, including that of The National Library of Medicine, suggests an association between injectable dMPA and meningioma, especially with prolonged use.
Because of this, courts are closely examining:
- Medical research
- Regulatory history
- Expert testimony
A report from the University of California San Francisco found that medical experts have noted some meningiomas can be influenced by hormones. Studies like this have contributed to ongoing research into potential risk factors.
Why 2026 Could Be a Major Year for Depo-Provera Litigation
Legal experts expect 2026 to be an important year for Depo-Provera lawsuits. Key developments include:
- Anticipated rulings on crucial legal defenses, such as preemption arguments
- Ongoing case management hearings throughout the year
- Preparation for early “bellwether” trials, which help test evidence and legal arguments
In many mass tort cases, bellwether trials are used to evaluate how juries respond to evidence. While these trials do not decide all cases, they can influence settlement discussions and litigation strategy.
How Courts Are Managing Depo-Provera Lawsuits
With thousands of claims being filed, courts typically use structured procedures to manage litigation efficiently. These procedures require plaintiffs to provide foundational evidence, such as showing a qualifying meningioma diagnoses and a use of Depo-Provera or a related product.
This early review process helps to make sure claims moving forward are supported by basic evidence. In many cases, people may need to provide:
- Medical records
- Insurance documentation
- Pharmacy records
These requirements are intended to streamline litigation and reduce delays in the process. An attorney can evaluate the facts of your case and determine if you qualify for a Depo-Provera claim.
When Medical Records Are Difficult to Obtain
A common challenge in Depo-Provera lawsuits involves obtaining older medical records. Because some people used Depo-Provera years ago, records may not be available due to standard retention practices.
Courts have acknowledged this issue, though. In certain cases, alternative forms of documentation may be allowed when individuals can demonstrate that they made reasonable efforts to obtain records.
Legal Claims in Depo-Provera Brain Tumor Lawsuits
There are several legal theories common in Depo-Provera claims.
Failure to Warn
Plaintiffs allege that they were not adequately warned by the manufacturer about potential risks associated with long-term use.
Product Liability
Claims focus on whether the drug may be considered unsafe due to undisclosed risks.
Negligence
Some Depo-Provera claims argue that the company failed to monitor safety data or update warnings in a timely manner.
An attorney can help with product liability claims involving dangerous pharmaceuticals. The process starts by evaluating the factors of your case to determine available legal options.
The Role of Multidistrict Litigation (MDL)
Depo-Provera cases are being handled through multidistrict litigation, which allows courts to coordinate large numbers of similar claims. An attorney can explain how mass tort litigation works for drug cases. MDL proceedings help:
- Address shared legal questions
- Streamline discovery
- Reduce duplication across cases
Unlike class actions, however, each claim remains individual. Because of this, outcomes may vary depending on the facts of each case.
Challenges in Depo-Provera Depo Shot Lawsuits in 2026
Despite the growing number of claims, these cases can be complex. For example, the documentation requirements and early case screening processes can present difficulties for some people, especially those with older claims.
Common challenges in Depo-Provera cases include:
- Establishing a connection between drug use and tumor development
- Navigating regulatory and legal defenses
- Addressing conflicting scientific research
Who May Be Eligible to File a Claim
Every case is unique, and eligibility depends on the facts of each situation. Individuals may consider exploring legal options if they:
- Received multiple injections over time
- Used Depo-Provera over an extended period
- Were later diagnosed with a meningioma or similar brain tumor
Factors that will also be considered include the timing of the diagnosis and severity of symptoms or required treatment. Availability of medical records may be reviewed for a Depo-Provera claim as well.
What This Means Going Forward
As Depo-Provera lawsuits continue to develop, several key trends are emerging:
- Courts are actively managing large numbers of claims
- Early procedural rulings are shaping how cases move forward
- Bellwether trials may provide insight into how juries evaluate these claims
As litigation progresses, these developments may affect settlement discussions. Future filings could also be influenced. A personal injury attorney will watch litigation closely to properly evaluate the facts of MDL Depo-Provera cases.
Speak With The Carlson Law Firm
If you or a loved one developed a brain tumor after using Depo-Provera, you may have the right to explore your legal options. A skilled attorney can explain how current litigation may apply to your situation.
The Carlson law Firm can review your medical and prescription history to evaluate whether a claim may be possible. We have experience working with individuals and families in mass tort cases and dangerous drug lawsuits like Depo-Provera. Speaking with a lawyer can help you better understand what steps may be available.
